Therpeutic drug monitoring of Everolimus in patients with renal cell carcinoma and tuberous sclerosis

Therpeutic drug monitoring of Everolimus in patients with renal cell carcinoma and tuberous sclerosis - TDM study of Everolimus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011559

Enrollment

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.advanced renal cell carcinoma 2.renal angiomyolipoma associated with tuberous sclerosis complex

Interventions

Everolimus 5mg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients given oral evelolimus more than 5mg daily

Exclusion criteria

Exclusion criteria: Pregnancy Interstitial lung marking in chest imaging Infection Liver dysfunction

Design outcomes

Primary

Measure	Time frame
Statistical difference of evelolimus trough level between adverse and non-adverse effect	—

Countries

Japan

Contacts

Public ContactToshiaki Shinojima

Keio University School of Medicine Department of Urology

t-shinoj@cd5.so-net.ne.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026